sorafenib has been researched along with cyclosporine in 7 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 377 | 2 | 170 |
| 6,520 | 730 | 5,251 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Bornhäuser, M; Brendel, C; Burchert, A; Charles, J; Ellenrieder, V; Gattenlöhner, S; Hessmann, E; Inselmann, S; Metzelder, SK; Michel, C; Neubauer, A; Rehberger, M; Sohlbach, K; Solovey, M; Stiewe, T; Ten Haaf, A; von Bonin, M; Wang, Y | 1 |
| Chen, YJ; Hsieh, CH; Huang, HL; Huang, YC; Tai, HC; Tsai, TH; Wang, LY | 1 |
2 review(s) available for sorafenib and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
5 other study(ies) available for sorafenib and cyclosporine
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance, Neoplasm; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured | 2015 |
Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Radiation; Enzyme Induction; Humans; Liver Neoplasms; Male; NF-kappa B; Portal Vein; Protein Kinase Inhibitors; Radiosurgery; Rats; Rats, Sprague-Dawley; Retrospective Studies; Sorafenib; Specific Pathogen-Free Organisms; Tissue Distribution; Venous Thrombosis | 2020 |